156 related articles for article (PubMed ID: 21149896)
1. mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.
Wesierska-Gadek J
Aging (Albany NY); 2010 Dec; 2(12):892-3. PubMed ID: 21149896
[No Abstract] [Full Text] [Related]
2. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
Leontieva OV; Blagosklonny MV
Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin, proliferation and geroconversion to senescence.
Blagosklonny MV
Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
[TBL] [Abstract][Full Text] [Related]
4. Shifting senescence into quiescence by turning up p53.
Serrano M
Cell Cycle; 2010 Nov; 9(21):4256-7. PubMed ID: 20980826
[No Abstract] [Full Text] [Related]
5. Senescence regulation by mTOR.
Dulic V
Methods Mol Biol; 2013; 965():15-35. PubMed ID: 23296649
[TBL] [Abstract][Full Text] [Related]
6. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.
Blagosklonny MV
Aging (Albany NY); 2012 Mar; 4(3):159-65. PubMed ID: 22394614
[TBL] [Abstract][Full Text] [Related]
8. The p53 inducing drug dosage may determine quiescence or senescence.
Lane DP; Verma C; Fang CC
Aging (Albany NY); 2010 Nov; 2(11):748. PubMed ID: 21068468
[No Abstract] [Full Text] [Related]
9. Rapamycin enhances long-term hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence.
Luo Y; Li L; Zou P; Wang J; Shao L; Zhou D; Liu L
Transplantation; 2014 Jan; 97(1):20-9. PubMed ID: 24092377
[TBL] [Abstract][Full Text] [Related]
10. Weak p53 permits senescence during cell cycle arrest.
Leontieva OV; Gudkov AV; Blagosklonny MV
Cell Cycle; 2010 Nov; 9(21):4323-7. PubMed ID: 21051933
[TBL] [Abstract][Full Text] [Related]
11. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.
Blagosklonny MV
Cell Cycle; 2011 Jul; 10(14):2295-8. PubMed ID: 21715978
[TBL] [Abstract][Full Text] [Related]
12. Growth stimulation leads to cellular senescence when the cell cycle is blocked.
Demidenko ZN; Blagosklonny MV
Cell Cycle; 2008 Nov; 7(21):3355-61. PubMed ID: 18948731
[TBL] [Abstract][Full Text] [Related]
13. Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling.
Halicka HD; Zhao H; Li J; Lee YS; Hsieh TC; Wu JM; Darzynkiewicz Z
Aging (Albany NY); 2012 Dec; 4(12):952-65. PubMed ID: 23363784
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels.
Goudarzi KM; Nistér M; Lindström MS
Cancer Biol Ther; 2014; 15(11):1499-514. PubMed ID: 25482947
[TBL] [Abstract][Full Text] [Related]
15. p53: The pivot between cell cycle arrest and senescence.
Santoro R; Blandino G
Cell Cycle; 2010 Nov; 9(21):4262-3. PubMed ID: 21057199
[No Abstract] [Full Text] [Related]
16. Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.
Shionome Y; Yan L; Liu S; Saeki T; Ouchi T
PLoS One; 2013; 8(1):e55457. PubMed ID: 23383195
[TBL] [Abstract][Full Text] [Related]
17. Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway.
Chauhan A; Ojha R; Semwal DK; Mishra SP; Semwal RB
Anticancer Agents Med Chem; 2017 Nov; 17(11):1545-1554. PubMed ID: 28270077
[TBL] [Abstract][Full Text] [Related]
18. The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases.
Zajkowicz A; Rusin M
Mech Ageing Dev; 2011; 132(11-12):543-51. PubMed ID: 21945951
[TBL] [Abstract][Full Text] [Related]
19. Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent Inhibition of sirtuin 1.
Back JH; Rezvani HR; Zhu Y; Guyonnet-Duperat V; Athar M; Ratner D; Kim AL
J Biol Chem; 2011 May; 286(21):19100-8. PubMed ID: 21471201
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
